{"schema":"hottub-news/prospects/v1","item":{"id":"n_unicwofbrv2sgeevgdbq","title":"Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio","title_en":null,"url":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","outlet":"biospectrumindia.com","published":"2026-11-18T05:07:00Z","sponsored":false,"page":"https://hottub.news/articles/n_unicwofbrv2sgeevgdbq"},"prospects":[{"name":"Biocon","kind":"organization","role":"named","entity":"wikidata:Q487694","source":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","note":"In the news: Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio (biospectrumindia.com, 2026-11-18)","reason":"Named in a headline on 2026-11-18: “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” (biospectrumindia.com)","group":"Organizations","add_url":"https://crm.joinhottub.com/relationships/add#name=Biocon&kind=organization&source=https%3A%2F%2Fwww.biospectrumindia.com%2Fnews%2F104%2F28835%2Fbiocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html&entity=wikidata%3AQ487694&note=In%20the%20news%3A%20Biocon%20gets%20US%20FDA%20approval%20for%20Pebrilzo%E2%84%A2%20Injection%2C%20biosimilar%20to%20Perjeta%C2%AE%2C%20expanding%20oncology%20portfolio%20%28biospectrumindia.com%2C%202026-11-18%29","propose":{"name":"Biocon","kind":"organization","reason":"Named in a headline on 2026-11-18: “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” (biospectrumindia.com)","requestId":"news:n_unicwofbrv2sgeevgdbq:wikidata:Q487694:b82e597a","sourceUrl":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","entity":"wikidata:Q487694"}},{"name":"United States Food and Drug Administration","kind":"organization","role":"named","entity":"wikidata:Q204711","source":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","note":"In the news: Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio (biospectrumindia.com, 2026-11-18)","reason":"Named in a headline on 2026-11-18: “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” (biospectrumindia.com)","group":"Organizations","add_url":"https://crm.joinhottub.com/relationships/add#name=United%20States%20Food%20and%20Drug%20Administration&kind=organization&source=https%3A%2F%2Fwww.biospectrumindia.com%2Fnews%2F104%2F28835%2Fbiocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html&entity=wikidata%3AQ204711&note=In%20the%20news%3A%20Biocon%20gets%20US%20FDA%20approval%20for%20Pebrilzo%E2%84%A2%20Injection%2C%20biosimilar%20to%20Perjeta%C2%AE%2C%20expanding%20oncology%20portfolio%20%28biospectrumindia.com%2C%202026-11-18%29","propose":{"name":"United States Food and Drug Administration","kind":"organization","reason":"Named in a headline on 2026-11-18: “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” (biospectrumindia.com)","requestId":"news:n_unicwofbrv2sgeevgdbq:wikidata:Q204711:b82e597a","sourceUrl":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","entity":"wikidata:Q204711"}},{"name":"biospectrumindia.com","kind":"organization","role":"outlet","website":"https://biospectrumindia.com/","source":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","note":"Published: Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio (2026-11-18)","reason":"Published “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” on 2026-11-18","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=biospectrumindia.com&kind=organization&website=https%3A%2F%2Fbiospectrumindia.com%2F&source=https%3A%2F%2Fwww.biospectrumindia.com%2Fnews%2F104%2F28835%2Fbiocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html&note=Published%3A%20Biocon%20gets%20US%20FDA%20approval%20for%20Pebrilzo%E2%84%A2%20Injection%2C%20biosimilar%20to%20Perjeta%C2%AE%2C%20expanding%20oncology%20portfolio%20%282026-11-18%29","propose":{"name":"biospectrumindia.com","kind":"organization","reason":"Published “Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio” on 2026-11-18","requestId":"news:n_unicwofbrv2sgeevgdbq:Outlet:7cb57966:13af1d07","website":"https://biospectrumindia.com/","sourceUrl":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html"}}],"someone_else":{"source":"https://www.biospectrumindia.com/news/104/28835/biocon-gets-us-fda-approval-for-pebrilzo-injection-biosimilar-to-perjeta-expanding-oncology-portfolio.html","note":"In the news: Biocon gets US FDA approval for Pebrilzo™ Injection, biosimilar to Perjeta®, expanding oncology portfolio (biospectrumindia.com, 2026-11-18)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}